Last reviewed 2026-04-23 · How we verify

Botulinum Toxin Type A - Vistabel

Inhibits acetylcholine release at the neuromuscular junction

Inhibits acetylcholine release at the neuromuscular junction Used for Frown lines, Forehead lines, Crow's feet.

At a glance

Mechanism of action

Botulinum toxin type A is a neurotoxin that blocks the release of acetylcholine, a neurotransmitter that transmits nerve impulses to muscles, thereby causing muscle relaxation and reducing muscle spasms.

Approved indications

• Frown lines
• Forehead lines
• Crow's feet

Common side effects

• Eyelid ptosis
• Diplopia
• Headache

Key clinical trials

• A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections (PHASE4)
• Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides (PHASE4)
• Study Comparing Treatment With Alluzience vs Reconstituted Toxin (PHASE4)
• Comparison of Two Botulinum Toxins Type A on Forehead Wrinkles (PHASE2)
• Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars (PHASE2, PHASE3)
• Long-Term Patient Satisfaction of Facial Aesthetic Treatment With BOTOX®
• Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines (PHASE4)
• Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Botulinum Toxin Type A - Vistabel CI brief — competitive landscape report
• Botulinum Toxin Type A - Vistabel updates RSS · CI watch RSS
• Galderma R&D portfolio CI